Top Markets
Coin of the day
Genflow Biosciences Plc Genflow Biosciences Plc

Genflow Biosciences Plc

GENF
Rank in Stocks #40421
Genflow Biosciences plc, together with its subsidiaries, engages in the... Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-1003, a topical delivery of SIRT6 to the fibroblasts in the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005, which addresses mitochondrial dysfunction observed in sarcopenia for muscle health and combat sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company has collaborative research agreements with Revatis SA and EXO Biologics for therapy medicinal products. Genflow Biosciences plc was founded in 2020 and is headquartered in London, the United Kingdom.
Share Price
$0.02653368
Market Cap
$150.29K
Change (1 day)
-4.41%
Change (1 year)
194.29%
Country
GB
Trade Genflow Biosciences Plc (GENF)

Category

Stock split history for Genflow Biosciences Plc (GENF)
Genflow Biosciences Plc stock (symbol: GENF) underwent a total of 0 stock splits.
The most recent stock split occurred on Aug 13, 2026.
One GENF share bought prior to Aug 13, 2026 would equal to 0 GENF shares today.
Stock split list
Year Split Multiple Cumulative Multiple
Not enough data for the provided dates.
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE